Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Bellicum Pharma (BLCM) to initiate Phase 1 trial of BPX-701 in patients with metastatic uveal melanoma in late 2016

Source Link:: http://seekingalpha.com/article/3958395-bellicum-pharmaceuticals-blcm-ceo-tom-farrell-q4-2015-results-earnings-call-transcript?part=single

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

BLCM

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details BPX-701 is a high affinity T cell receptor or TCR product candidate incorporating BLCM's CaspaCID safety switch and is designed to target malignant cells expressing the preferentially-expressed antigen in melanoma or PRAME

http://seekingalpha....

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Nov 09, 2016

Occurred Source:

http://ir.bellicum.com/phoenix.zhtml?c=253830&ut=1478730913&p=RssLanding&cat=news&id=2221084

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Phase 1 Trial, Metastatic Uveal Melanoma, Bpx-701, T Cell Receptor, Tcr Product, Melanoma